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Quantification of The FLI1 Gene Expression By
Real-Time Quantitative RT-PCR

Abstract: In this study, quantification levels
were investigated to define alterations in the
expression of the FLI1 gene on acute
promyelocytic leukemia (APL), which is
characterized by a reciprocal t(15,17)
translocation of fusing the PML gene to the
retinoic acid receptor alpha (RAR alpha) gene.
The FLI1 gene plays an important role in
several signal transduction pathways, and is
involved in the normal regulation of myeloid
hematopoiesis and leukomogenesis. We used
the
real-time
quantitative
RT-PCR
(LightCycler) with SYBR Green I dye method
for the labeling and analysis of the
quantification of FLI1 gene RT-PCR products.
Ribosomal protein S9 (RPS9) was used as an
internal control for the normalization of the
results. FLI1 gene levels were found up-

Introduction
There are several methods to quantify gene
expression including northern blotting, (1), cDNA array
(2), RNAse protection assay (3,4), and RT-PCR (5). cDNA
array technology is able to calculate tens of thousands of
genes in a single experiment, but is limited in use due to
its high cost. Northern analysis is a method providing
information about mRNA size and the RNA integrity.
RNAse protection assay is very useful for discriminating
between related mRNAs of the same size. Both of these
technologies are valuable methods, but low detection
sensitivity is a problem they share. The focus on
increasing sensitivity has led to the development of highly
complex procedures such as three-step nested RT-PCR
(6), but these procedures increase the possibility of
contamination and false positive results (7). Real-time
quantitative RT-PCR is the most sensitive, rapid and
reliable approach compared to conventional methods and
cDNA array technology (2,8,9).
It was found that the FLI1 gene was down-regulated
during vitamin D dependent differentiation of acute
myeloid leukemia cell line HL60 cells in a previous study
using cDNA array technology and real-time quantitative

regulated in two PMLRARA fusion gene
positive APL patients compared to bone
marrow samples from four healthy donors.
To our knowledge, this study is the first
attempt to quantify the FLI1 gene in APL
patients by real-time RT-PCR. SYBR Green I
dye detection and product verification by
melting curve analysis is a rapid, sensitive and
specific method to validate the expression of
the FLI1 gene. Based on our findings, this
method should be considered to be a
successful approach to gene statement
analysis.
The possible correlation of high
expression levels of FLI1 in APL pathogenesis
remains to be established.
Key Words: Gene expression, FLI1, PMLRARA, Real Time RT-PCR.

RT-PCR (10). This finding indicated that an
overexpressed FLI1 gene may play a role in acute
promyelocytic leukaemia (APL) pathogenesis. The role of
the FLI1 gene in myeloid leukemogenesis and normal
regulation of myeloid hematopoiesis has been shown also
in previous studies by other authors (11,12).
Our aim was to perform statement analysis of the
FLI1 gene in APL t(15;17) cases using real-time
quantitative RT-PCR (LightCycler, Roche Diagnostics
GmbH, Germany). To our knowledge, this study is the
first attempt at the quantification of the FLI1 gene in APL
patients by real-time quantitative RT-PCR.

Materials and Methods
Patient Samples
This retrospective study is based on total RNA
samples extracted from the bone marrow aspirates of
two APL patients. The PMLRARA fusion gene was
detected for diagnostic purposes in the Genetics
Department of the Institute for Experimental Medicine,
‹stanbul University by RT-PCR analysis, and samples were
collected from the Adult Hematology/Oncology Division of
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‹stanbul Medical Faculty, ‹stanbul University. The control
group consisted of pooled bone marrow aspirates from
four healthy volunteer.
RNA Isolation
Mononuclear cells from bone marrow aspirates were
isolated by ficoll-hypaque centrifugation. Total RNA was
extracted by using the guanidinium thiocyanate-phenolchloroform extraction method as previously described
(13). The quality of the RNA was checked by agarose gel
electrophoresis. cDNA was synthesized from 1 µg of total
RNA by using random hexamers (14).
Validation of Relative Gene Expression by
Quantitative Fluorescent PCR
DNA Master SYBR Green 1 mix (Roche, Mannheim,
Germany) was used with 2 µl of cDNA and with 10 pmol
of the primers. PCR was performed on a “LightCycler”, a
rapid thermal cycling instrument of Roche (Roche
Diagnostics GmbH, Germany), in capillary glass tubes
with the LightCycler-Fast Start DNA Master SYBR Green
I kit (Roche). During the amplification, SYBR Green was
binding to double stranded PCR products and so the
fluorescence signal synchronically increased with the
increasing amount of the product. Work was always
carried out on desktop coolers (pre-cooled to 4 °C). The
master mixtures were prepared exactly according to the
recommendations of the manufacturer, except for the
concentrations of Mg+2, primers and volume of cDNA.
Final concentrations in the reaction mixtures of these
were Mg+2, 2.5 mM and primers, 50 pmol each. The
accession numbers, chromosomal locations and sequences
of gene-specific primers are shown in Table 1. The
amplification program consisted of 1 cycle of 95 °C with
a 60 s hold, followed by 45 cycles of 95 °C with a 10 s
hold, annealing temperature at 55 °C with a 5 s hold, and
72 °C with a 20 s hold. Amplification was followed by
melting curve analysis using the program run for one
cycle at 95 °C with a 0 s hold, 65 °C with a 10 s hold,
and 95 °C with a 0 s hold at step acquisition mode. A
negative control without cDNA template was run with
Table 1.

every assay to assess overall specificity. Each assay
included duplicate reactions for each dilution and was
repeated. Standard curves were obtained by using serial
dilutions of the beta-globulin gene (DNA Control kit,
Roche) according to the supplier’s instructions. The
concentration of each gene was determined on the basis
of a kinetic approach using the LightCycler software. The
obtained gene expression values were normalized using
housekeeping gene RPS9 levels of pooled bone marrow
aspirates from four healthy subjects. Melting curve
analysis and the gel electrophoresis of the products
validated the reactions. Ratios were calculated using the
following formula:
The measured expression of the FLI1 gene in patients / The
measured expression of the housekeeping RPS9 gene in patients
Ratio =
The measured expression of the FLI1 gene in pooled healthy
bone marrow samples / The measured expression of the
housekeeping RPS9 gene in pooled healthy bone marrow
samples

Results
FLI1 gene expressions were investigated in two
t(15;17) APL patients. The first patient had a bcr1/2
type breakpoint on the PML gene and FLI1 gene levels
were found eight times up- regulated. The second patient
had a bcr3 type breakpoint on the PML gene and FLI1
gene levels were found 24 times up-regulated compared
to the pooled bone marrow samples of four healthy
donors (Table 2).
Amplification reactions demonstrated the gradual
reduction in fluorescence as temperature increases. The
rapid falls indicate the specific products that melt at
specific temperatures as 85 °C for FLI1 and 86 °C for
RPS9. Gene specific amplifications were demonstrated
with melting curve data (Figure 1) and the presence of
PCR products of the expected size in agarose gel
electrophoresis (Figure 2).

Primer sequences of the studied genes.

Genes

Chromosomal Location

Accession Number (GenBank)

Primer Sequences

RPS9 (Housekeeping)

19q13.4

U14971

FLI1

11q24.1-q24.3

M93255

CGTCTCGACCAAGAGCTGA
GGTCCTTCTCATCAAGCGTC
CCACACTGGTGACACAGGAG
TCTTTGACACTCAATCGTGAGGA
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Table 2.

Validation of relative gene expression by quantitative realtime RT- PCR (compared to bone marrow samples of four
healthy donors).

Patients

Age/sex

Break Point

FLI1 ratio

1
2

44 (M)
26 (F)

bcr1/2
bcr3

8
24

In this study we analyzed the expression levels of FLI1
gene in two APL patients who carry t(15;17). We used
the real-time (kinetic) RT-PCR with SYBR Green I dye
method for the labeling and quantification analysis of PCR
products. Our method is considered rapid, sensitive and
specific to validate gene expression (15).
At present, the normalization of the amplification
product is the main problem of quantitative RT-PCR.
Quantification errors are easily obtained by variations in
the amount of starting material between different
samples. The main approach for minimizing these errors
is through using cellular RNA as an internal reference

Figure 1.

Specific amplifications of FLI1 and
40SR9. Melting curve analysis of a
FLI1 and RPS9 amplification reactions demonstrating the gradual
change in fluoresence as temperature increases. The rapid falls indicates the specific products melt at
specific temperatures, 85 °C for
FLI1 and 86 °C for RPS9.

Figure 2.

Reactions were analyzed by
agarose gel electrophoresis and
revealed single amplification products of the predicted sizes (Lane 1,
Marker ; Lane 2,3. Beta globulin
housekeeping gene*, 110 bp; Lane
4,6. FLI1 oncogene 242 bp; Lane
5,7. RPS9 housekeeping gene
132 bp; Lane 8, Marker.
* Beta globulin housekeeping gene
from DNA control kit (Roche,
Mannheim, Germany) used to
obtain standard curves by serial
dilutions.
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The measured expression of the FLI1 gene in patients / The
measured expression of the housekeeping RPS9 gene in
patients
*Ratio =
The measured expression of the FLI1 gene in pooled healthy
bone marrow samples / The measured expression of the
housekeeping RPS9 gene in pooled healthy bone marrow
samples

Discussion

Temperature (°C)
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(16). The ideal gene used for normalization should be
expressed at a constant level in different tissues at all
stages of development, and should not be affected by any
type of disease. Housekeeping GAPDH (15), Beta actin
(17) and ribosomal RNA are the genes most commonly
used to normalize patterns of gene expression. rRNA
sequences have been shown to be more reliable than
either of the housekeeping genes in human and mouse
malignant cell lines (18,19). For this reason, we used
ribosomal protein S9 (RPS9) as an internal control for
the normalization of our quantification results.
We optimized PCR reactions for comparative
quantification of FLI1 and RPS9. It is important that
these primers were working free of primer-dimer
complexes in normal conditions. However, after each
reaction, melting peak analysis is the step to be
remembered, but not the agarose gel run of the products.
The sequence of the work was as follows: a) cDNAs were
diluted in eppendorf tubes to obtain a series, b) the
primers were distributed in capillary tubes, c) the master
mixture was prepared by mixing a sufficient amount of
Mg into the ready-to-use mixtures, d) the master mixture
was divided into 0.5 ml eppendorf tubes (always on the
cooler). Mixing was achieved by pipetting and later the
mixtures were distributed over the capillary tubes. This
sequence was important to ensure the presence of
equivalent amounts of sample cDNA for different primers
and reactions.
ETS family members have been shown to play an
important role in several signal transduction pathways
(11). The human FLI1 gene is an ETS family member and
is involved in malignancies in both humans and mice. The
overexpression of FLI1 perturbs normal lymphoid cell
function and apoptosis (20,21 ). FLI1 also prevented the
rapid down-regulation of cyclin D2 and D3 expression
normally observed during Epo-induced differentiation and
delayed the down-regulation of several other genes
involved in cell cycle or cell proliferation control. It has
been suggested that the maintenance of high levels of
cyclin D2 and D3 in FLI1 expressing erythroblasts could
therefore also contribute to the deregulation of the
normal control of the balance between proliferation and
differentiation (22). Obtained results showed that the
FLI1 gene is overexpressed in patients compared with
that in healthy donors. These results were in parallel with
the findings of a previous study which demonstrated the
down-regulation FLI1 gene in vitamin D dependent
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differentiation of promyelocytic leukemia cell line HL 60
at 72 h of cultures, using cDNA array technology (10).
There are other quantification studies of the FLI1
gene in the literature, but most of these studies concern
the quantification of the EWS-FLI1 fusion in Ewing’s
sarcoma family tumors. A significantly better treatment
outcome was reported for a limited number of patients
with localized disease when the tumors expressed a type
1 EWS-FLI1 fusion compared with tumors that expressed
a non-type 1 EWS-FLI1 fusion. This raised the question of
whether EWS-FLI1 gene fusion type might serve as a
prognostic molecular indicator in this group of patients
(23-25). On the other hand, Levanon et al. (26) obtained
results related to the FLI1 gene while they were studying
the architecture of the genomic locus encoding the human
leukemia-associated transcription factor RUNX1/AML1.
They found that the FLI1 homologous sequence contains
a breakpoint of the t(11;22) translocation associated
with Ewing's tumors, and may have a similar function in
RUNX1. Taken together, these data suggest that the FLI1
gene also plays an important role in tumorigenesis in
fusion forms with other genes.
Based on our findings, the real-time quantitative
(kinetic) RT-PCR (LightCycler) method should be
considered a successful approach for gene statement
analysis and here we propose an optimized strategy for
FLI1 gene detection.
Larger studies are required to
assess the impact of our approach to FLI1 gene
expression analysis in myeloid leukomogenesis. The
possible correlation of high expression levels of FLI1 to
APL pathogenesis remains to be established.
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